Aerovate Therapeutics Inc
AVTE2.680USD
0.0000.00%
收盤 03/30, 16:00（美東）報價延遲15分鐘
77.68M總市值
虧損本益比TTM
關於 Aerovate Therapeutics Inc 公司
Aerovate Therapeutics Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發能夠顯著改善罕見心肺疾病患者生活的藥物。其最初的重點是推進 AV-101，這是一種用於治療肺動脈高壓 (PAH) 的伊馬替尼乾粉吸入劑型，這是一種影響美國和歐洲約 70,000 人的毀滅性疾病。口服伊馬替尼在 PAH 患者的主要終點、六分鐘步行距離和多個次要血流動力學終點方面也表現出統計學上的顯著改善。AV-101 使用乾粉吸入器輸送，旨在提供等於或高於口服劑量的肺部濃度，同時限制藥物的全身水平。PAH 是一種醫療需求尚未得到滿足的罕見病，其特徵是將血液從心臟右側輸送到肺部的血管壓力較高。
Aerovate Therapeutics Inc簡介
公司代碼AVTE
公司名稱Aerovate Therapeutics Inc
上市日期- -
CEOMr. Timothy P. Noyes
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址930 Winter Street
城市WALTHAM
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02451
電話16174432400
網址https://www.aerovatetx.com/
公司代碼AVTE
上市日期- -
CEOMr. Timothy P. Noyes
Aerovate Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
505.00
+1.84%
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Marinus Verwijs, Ph.D.
Dr. Marinus Verwijs, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Ralph Niven, Ph.D.
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Director
Independent Director
--
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua Resnick, M.D.
Dr. Joshua Resnick, M.D.
Independent Director
Independent Director
--
--
Mrs. Susan Fischer
Mrs. Susan Fischer
Executive Vice President - Development Operations
Executive Vice President - Development Operations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
505.00
+1.84%
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Marinus Verwijs, Ph.D.
Dr. Marinus Verwijs, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Ralph Niven, Ph.D.
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 2月19日 週四
更新時間: 2月19日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
13.73%
Fairmount Funds Management LLC
9.23%
RA Capital Management, LP
7.44%
Bellevue Asset Management AG
6.77%
VR Adviser, LLC
6.53%
其他
56.29%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
13.73%
Fairmount Funds Management LLC
9.23%
RA Capital Management, LP
7.44%
Bellevue Asset Management AG
6.77%
VR Adviser, LLC
6.53%
其他
56.29%
股東類型
持股股東
佔比
Investment Advisor
35.41%
Hedge Fund
24.72%
Investment Advisor/Hedge Fund
20.15%
Venture Capital
20.11%
Individual Investor
1.36%
Private Equity
1.08%
Research Firm
0.32%
Bank and Trust
0.15%
Pension Fund
0.04%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
225
39.61M
80.33%
+327.27K
2025Q3
217
31.51M
96.73%
+18.51M
2025Q2
214
13.42M
41.64%
+12.20M
2025Q1
214
927.53K
47.43%
-347.78K
2024Q4
217
30.84M
106.81%
-7.10M
2024Q3
214
28.32M
98.10%
-8.69M
2024Q2
210
27.84M
96.65%
-3.71M
2024Q1
181
29.16M
104.58%
-1.74M
2023Q4
173
28.88M
104.29%
-1.94M
2023Q3
168
28.55M
103.17%
-3.10M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
4.79M
9.71%
+53.40K
+1.13%
Sep 30, 2025
Fairmount Funds Management LLC
4.55M
9.23%
--
--
Dec 17, 2025
RA Capital Management, LP
3.21M
6.52%
--
--
Dec 17, 2025
VR Adviser, LLC
3.22M
6.53%
--
--
Dec 17, 2025
Janus Henderson Investors
3.06M
6.21%
--
--
Dec 17, 2025
BlackRock Institutional Trust Company, N.A.
1.96M
3.98%
+401.34K
+25.73%
Sep 30, 2025
The Vanguard Group, Inc.
1.73M
3.5%
-80.84K
-4.47%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Value ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
ProShares Hedge Replication ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
ALPS Medical Breakthroughs ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.06%
iShares Russell 2000 Value ETF
佔比0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.02%
ProShares Hedge Replication ETF
佔比0.02%
Proshares Ultra Russell 2000
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
ALPS Medical Breakthroughs ETF
佔比0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
